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An association between lower educational attainment (EA) and an increased risk for depression 
has been confirmed in various western countries. This study examines whether pleiotropic genetic 
effects contribute to this association. Therefore, data were analyzed from a total of 9,662 Major 
Depressive Disorder (MDD) cases and 14,949 controls (with no lifetime MDD diagnosis) from the 
Psychiatric Genomics Consortium with additional Dutch and Estonian data. The association of EA 
and MDD was assessed with logistic regression in 15,138 individuals indicating a significantly 
negative association in our sample with an odds ratio for MDD 0.78 [0.75–0.82] per standard 
deviation increase in EA. With data of 884,105 autosomal common SNPs, three methods were 
applied to test for pleiotropy between MDD and EA: (i) genetic profile risk scores (GPRS) derived 
from training data for EA (independent meta-analysis on 120,000 subjects) and MDD (using a ten-
fold leave-one-out procedure in the current sample) (ii) bivariate Genomic-Relationship-Matrix 
Restricted Maximum Likelihood (GREML), and (iii) SNP effect concordance analysis (SECA). 
With these methods we found (i) that the EA-GPRS did not predict MDD status, and MDD-GPRS 
did not predict EA, (ii) a weak negative genetic correlation with bivariate GREML analyses, but 
this correlation was not consistently significant, (iii) no evidence for concordance of MDD and EA 
SNP effects with SECA analysis. To conclude, our study confirms an association of lower EA and 
MDD risk, but this association was not due to measurable pleiotropic genetic effects, which 
suggests that environmental factors could be involved such as, for example, socioeconomic status.
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Depression; Educational Attainment; Genetic Correlation; Pleiotropy
Introduction
An association between lower educational attainment (EA) and increased risk for Major 
Depressive Disorder (MDD) has been confirmed in various Western countries. A meta-
analysis of 37 studies from mainly western countries found a 3 per cent decrease in log odds 
ratio for depression per additional year of education.1 Research of the World Mental Health 
Survey Initiative also found that those with high educational levels are generally at lower 
risk for depression in high-income countries, although Japan showed an inverted 
association.2 The international Consortium of Psychiatric Epidemiology found a negative 
correlation in the United States and the Netherlands,3 which was confirmed in a recent study 
in the Netherlands.4
The association of lower EA and increased MDD risk could result from multiple, not 
necessarily independent, effects; including causal, environmental or pleiotropic genetic 
effects. Lower EA could lead to an increased MDD risk (social causation), for example via 
stress associated with lower socioeconomic status, or via less effective coping strategies or 
unhealthier lifestyles among those with lower EA.5,6 However, lower EA could also be the 
result of MDD vulnerability, for example when the onset of MDD is at an early age before 
educational goals would have been achieved. Alternatively, a third factor could be in play 
impacting on both, such as personality characteristics or less developed cognitive abilities, 
causing lower EA and increased risk for MDD. Such a third factor could also consist of 
pleotropic genetic effects (or linkage disequilibrium between effective variants) resulting in 
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genetic correlation (the part of the phenotypic correlation caused by shared additive genetic 
effects), because EA7 and MDD8–10 both have a confirmed genetic basis.
It is relevant to understand the mechanisms of the association between lower EA and MDD, 
because this can have important implications for prevention strategies of MDD and its 
consequences. When lower EA would increase MDD risk, the responsible mechanisms 
should be studied and subsequently addressed, for example by providing psycho-education 
about these mechanisms to those with lower EA. However, when shared genetic effects 
would link EA and MDD no responsible mechanisms can be addressed, and prevention 
would be restricted to general advice to prevent MDD.
The possible impact of pleiotropic genetic effects on lower EA and increased MDD risk has 
not received much study. We are aware of three such studies, of which two find a substantial 
negative genetic correlation between EA and cross-sectional measures of depressive 
symptoms obtained via self-report questionnaires.11,12 One study used DSM-IV based 
diagnosis of MDD with a twin design and generally supported the social causation model 
and found only a small genetic correlation.5 To the best of our knowledge, no study 
combined DSM-IV based diagnosis and genome-wide SNP data to test for pleiotropic 
genetic effects between lower EA and MDD risk.
The current study was conducted to test for pleiotropic genetic effects between lower EA 
and MDD diagnoses in a large sample of ~25,000 subjects from the Psychiatric Genomics 
Consortium13 with additional Estonian and Dutch data. We applied the following SNP-
based methods: genetic profile risk score (GPRS) analyses, bivariate Genomic-Relationship-
Matrix Restricted Maximum Likelihood (GREML) analysis, and SNP effect concordance 
analysis (SECA).
Methods
Subjects
Genotype and phenotype data of ten cohort studies were combined: eight cohorts14–21 
included in the Psychiatric Genomics Consortium (PGC)13 plus two additional cohorts. The 
first additional cohort was from the Netherlands and combined additional independent data 
from the Netherlands Study of Depression and Anxiety22 and the Netherlands Twin 
Registry23 (NESDA/NTR-2). The second additional cohort was a population-based sample 
from Estonia (EGCUT).24 The numbers of cases and controls per cohort are displayed in 
Table 1.
MDD cases and controls
All cases (N=9,662) had a DSM-IV or ICD-10 based diagnosis of MDD in lifetime 
according to a structured diagnostic instrument. Most controls (N=14,949) were randomly 
selected from the population and screened for a lifetime history of MDD. A more detailed 
description of the PGC-cohorts was given previously13 and is summarized in Supplementary 
Table 1. For the NESDA/NTR-2 cohort, MDD-cases were diagnosed with the DSM-IV 
based CIDI interview (CIDI, version 2.1), and controls scored low on various mental health 
screening questionnaires (NTR)25 or had no diagnosis of a psychiatric disorder in their 
Peyrot et al. Page 3
Mol Psychiatry. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
lifetime (NESDA). For the EGCUT cohort, MDD-cases were identified using International 
Classification of Diseases (ICD-10) codes F32 (depressive disorder) and/or F33 (recurrent 
depressive disorder), and MDD-controls excluded all subjects with a lifetime ICD10 
psychiatric diagnosis (category F).24
Educational attainment
Educational attainment (EA) was assessed in seven of the ten contributing cohorts (EGCUT, 
GenRED, GSK, NESDA/NTR-1, NESDA/NTR-2, QIMR, and STAR-D). For NESDA/
NTR-1 and NESDA/NTR-2, EA was defined as the years of education required for the 
highest diploma attained following the Dutch educational system. For QIMR and EGCUT, 
EA was defined as the US years of education required for the highest diploma attained 
following the international ISCED classification.7 For GSK, EA was defined as the number 
of years that school was attended. For STAR*D, EA was expressed in years of education. 
For GenRED, EA was assessed in controls only as the highest diploma attained and ranged 
from 1 to 5 labeling the following educational levels: lower than high school (1), high 
school (2), some college (3), bachelor degree (4), higher than bachelor degree (5).
The EA measure was corrected per cohort for year of birth and sex, in line with the recent 
meta-analysis from the Social Science Genetic Association Consortium.7 Thereby, the 
standardized residuals were obtained after regression of EA on sex, year of birth (YOB), 
YOB2, YOB3, and the interaction of sex with YOB, YOB2, and YOB3. For STAR*D and 
GSK, YOB was not available and substituted with age. In all cohorts, EA was defined in 
individuals over 25 years of age only, so that they had time to achieve their educational 
potential. The distribution of EA z-scores is displayed in Supplementary Figure 1.
Genotyping, quality control, and imputation
Genotyping, quality control, and imputation were performed in line with previous 
publications and are described in detail in the Supplementary Materials. In short, quality 
controlled SNPs with a MAF > 0.01 from the HapMap3 reference panel26 were imputed and 
yielded information on 884,105. With these SNPs the Genomic-Relationship-Matrix was 
estimated and unrelated subjects selected (with maximum pairwise genetic relationships 
0.05, which is approximately equivalent to second cousins), using the GCTA software.27 All 
of the subsequent genetic analyses were corrected for possible confounding cohort- and 
genotyping effects by including a categorical covariate labeling the ten cohorts, and within 
cohorts the different genotyping batches, where applicable (i.e. three batches within 
NESDA/NTR-2, two batches within EGCUT, and two batches within QIMR). Ancestry-
informative principal components were based on the Genomic-Relationship-Matrix and 
estimated with the GCTA software.27
Genetic Profile Risk Scores (GPRS)
Preparation of the genetic profile risk scores based on EA discovery results (EA-GPRS) and 
MDD discovery results (MDD-GPRS) is described in detail in the Supplementary Materials. 
In short, the procedure from Purcell et al28 implemented in Plink29 was applied. The 
independent EA discovery results were from the recent meta-analyses on US years of 
schooling from the Social Science Genetics Association Consortium (SSGAC)7 containing 
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around 120,000 subjects. EA-GPRS analyses were not conducted for BMH, GenRED, and 
STAR*D, because no independent discovery results were available. To obtain the MDD 
discovery results was slightly more elaborate, because no large MDD cohort exists that is 
independent from PGC. Therefore, a ten-fold leave-one-cohort-out approach was followed, 
and the discovery results were thus based on around 8,000 cases and 12,000 controls.
The GPRS were based on the same set of independent SNPs. First, the SNPs were selected 
with results available for all of the discovery sets. Second, this set of SNPs was pruned to a 
set of 76,516 independent SNPs with a maximum pairwise r2 of 0.25 based on a sliding 
window of 200 SNPs with steps of 5 SNPs.29 The EA-GPRS and MDD-GPRS were then 
estimated based on all SNPs up to p-value thresholds (PT) in the respective discovery results 
of 0.001, 0.01, 0.1, and 1 respectively. Consequently, all GPRS with PT = 1 were based on 
the exact same SNPs, but GPRS with different PT were based on different sets of SNPs 
depending on the respective discovery results (see Supplementary Table 2). The GPRS were 
standardized per cohort to a mean of 0 and standard deviation of 1 to aid interpretability of 
results.
Statistical analyses
The association of EA to MDD risk (phenotypic correlation) was assessed with logistic 
regression within EGCUT, GSK, NESDA/NTR-1 and 2, QIMR, and STAR*D separately, 
and in the combined sample correcting for covariates labeling the cohorts.
Genetic Profile Risk Score analyses—In the first method to test for pleiotropic 
genetic effects we estimated the across-trait effects of EA-GPRS on MDD and, vice versa, 
the effects of MDD-GPRS on EA. For comparison, we also estimated the within-trait effects 
of EA-GPRS on EA and MDD-GPRS on MDD. The effects of GPRS on EA and MDD were 
assessed with linear and logistic regression respectively. For the full sample, the effects were 
assessed for the GPRS based on PT of 0.001, 0.01, 0.1, and 1; for the individual cohorts, the 
effects were only assessed for the GPRS based on PT = 1.
The proportions of variation explained in EA and MDD were estimated as additional 
measures of the impact of GPRS. For EA, this proportion was derived as the R2 of the linear 
regression model including the covariates and the polygenic risk score, minus the R2 of the 
model including the covariates only. For MDD, Nagelkerke’s pseudo R2 were derived and 
corrected for the covariates by substituting the null (or intercept) model in Nagelkerke’s 
equation for the model including the covariates (adjusted equation in Supplementary 
Materials). Lee at al indicated that Nagelkerke’s pseudo R2 can be biased by ascertainment, 
when the proportion of cases in the study sample differs from the population disease 
frequency.30 Therefore, they proposed an R2 measure that is robust against ascertainment 
bias and interpretable on the liability scale. This liability R2 was obtained by rescaling 
Nagelkerke’s R2 for an MDD population prevalence of K=0.2 (see Supplementary 
Materials).30
Bivariate Genomic-Relationship-Matrix Restricted Maximum Likelihood 
(GREML)—The GREML mixed linear model method was used (i) to assess the proportion 
of variation in EA and MDD explained by genome-wide common SNPs (SNP-h2) and (ii) to 
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assess the pleiotropic genetic effects between MDD and EA (genetic correlation), as 
implemented in GCTA.27,31,32 The MDD SNP-h2 was expressed on the liability scale for a 
population prevalence of K=0.2 by converting the SNP-h2 on the observed scale (controls 0; 
cases 1) with equation (23) from Lee et al.33 Bivariate GREML estimates of the genetic 
correlation are approximately the same on the liability scale as on the observed scale,32 
which implies that (i) its value does not depend on population disease prevalence K and (ii) 
that the genetic correlation between the binary MDD status and continuous EA measure 
could be estimated. The genetic correlation was, first, estimated with EA information from 
both cases and controls. This estimate could, however, potentially be confounded by case 
ascertainment (which may not be education independent). Therefore, the genetic correlation 
was estimated a second time with EA information from controls only and MDD status from 
both cases and controls. The GPRS- and GREML-analyses were corrected for sex, the first 
10 (GPRS) or 20 (GREML) principal components and covariates labeling the cohorts and 
genotype batches. The necessity to correct for the principal components is indicated by a 
significant correlation between some of the GPRS with some of the principal components 
(Supplementary Table 3).
SNP effect concordance analysis (SECA)—In SNP effect concordance analysis 
(SECA; http://neurogenetics.qimrberghofer.edu.au/SECA)34 association results are 
analyzed, rather than individual genotyped data, to test for concordance between two traits 
with respect to the SNP effects significance as well as their directions. We applied SECA on 
the EA meta-analyses results from the Social Science Genetics Association Consortium 
(SSGAC)7 and MDD association results on our own sample.
Results
The overall sample consisted of 9,662 patients with MDD in lifetime and 14,949 controls 
with a mean age of 46.2 (SD 15.6) and 59.4% female; information on EA was available for 
5,373 cases and 9,765 controls (Table 1). In all cohorts with EA information available for 
both cases and controls, the phenotypic associations between EA and MDD was negative, 
with an overall odds ratio of 0.78 (95%CI: 0.75–0.82, p=2.2e-31) per standard deviation 
increase in EA (Figure 1). This negative association was consistent for MDD cases with 
known age of onset > 30. The strongest association was found in GSK with an OR of 0.45 
(95%CI: 0.40–0.50). When GSK was left out of the analyses, the overall association 
remained significant with an OR of 0.88 (95%CI: 0.84–0.92). The association was 
comparable in male and female (Supplementary Figure 2).
GPRS analyses
The GPRS had within-trait predictive effects as expected. The MDD-GPRS predicted MDD 
with most predictive power for the polygenic risk score including all SNPs (PT=1), with an 
odds ratio of 1.13 (p=1.7e-16) and an R2 of 0.4% on the liability scale (Table 2A). The EA-
GPRS predicted EA also in the expected direction, again with most predictive power for 
GPRS including all SNPs, with a beta of 0.11 (p=2.7e-37) and an R2 of 1.2% (Table 2A). 
However, we found no significant across-trait prediction: the MDD-GPRS did not predict 
EA (beta=−0.01 p=6.7e-2) and the EA-GPRS did not predict MDD (OR=0.99 p=5.9e-1, 
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Table 2A). Secondary analyses, performed within all cohorts separately, indicated that the 
within-trait predictive effects were consistent in all cohorts, and that the lack of across-trait 
predictive power was also consistent for all cohorts (Table 2B). In addition, no correlation 
was found between the MDD-GPRS and the EA-GPRS themselves (PT=1; correlation 
coefficient of 0.006, p=0.413). In additional analyses, across-trait predictive effects on MDD 
were tested for GPRS based on the SSGAC EA outcome tagging College completion 
(College-GPRS).7 College completion distinguishes more in the extreme end of the EA 
distribution, and has a confirmed genetic basis.7 However, no predictive effects of the 
College-GPRS on MDD were found (OR=0.99, p=0.74 for PT=1; Supplementary Table 4).
GREML analyses
GREML analyses in the overall study sample generated an estimate of MDD SNP-h2 of 
0.173 (SE=0.017, p<1e-16) on the liability scale (K=0.2); this finding was not solely driven 
by one of the individual cohorts, because the MDD SNP-h2 was estimated at consistent 
values when one cohort was left out at the time (Table 3). The MDD SNP-h2 was larger 
when expressed on the liability scale (0.173) than on the observed scale (0.126), with a 
larger SNP-h2 for larger values of disease frequency (as expected from equation (23) from 
Lee et al33; Supplementary Table 5). The EA SNP-h2 was estimated at 0.124 (SE=0.019, 
p=2.8e-11) when EA information in both cases and controls was taken into account (Table 
3A), and at 0.144 (SE=0.030, p=1.5e-6) when EA information of controls only was utilized 
(Table 3B). Again, these estimates were not solely driven by one of the individual cohorts 
(Table 3). The genetic correlation between MDD and EA was estimated at −0.253 
(SE=0.087, p=0.004) when EA information of both cases and controls was taken into 
account (Table 3A). Since a correlation between genetic and environmental factors is likely 
to be partitioned into the genetic variance and covariance components, we explored the 
robustness of this estimate by limiting EA to be measured only in controls. When taking into 
account EA of controls only and MDD status from cases and controls, the genetic 
correlation dropped considerably and was no longer significantly different from 0 with an 
estimate of −0.110 (SE=0.105, p=0.298; Table 3B). In post-hoc analyses we tested if EA 
moderated the polygenic effects on MDD, but found no such evidence with neither GPRS- 
nor GREML-analyses (Supplementary Materials).
SNP effect concordance analysis
SECA showed no evidence for genetic correlation. The primary SECA test divided the SNPs 
in 144 subsets based on significance of association with MDD and EA smaller than 
respectively 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1.0. Not a single of these 
subsets contained a larger number of SNPs than expected by chance, i.e. no concordance 
was found with respect to the MDD and EA SNP effect significances. When comparing the 
directions of SNP effects, only four of the 144 subsets showed nominally correlated 
directions of effect, which is not more than expected by chance (permuted empirical p-value 
0.244), indicating no concordance with respect to the MDD and EA SNP effect directions.
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Discussion
This study tested the existence of pleiotropic genetic effects (genetic correlation) between 
major depressive disorder (MDD) and lower educational attainment (EA) on individual 
genotype data from a large sample of approximately 25,000 subjects from Western 
countries. To start, a strong negative phenotypic association was found with an OR for 
MDD of 0.78 per SD increase in EA, which is in line with findings from a meta-analysis of 
37 studies from mainly western countries by Lorant et al.1 Our first test for genetic 
correlation was negative with no across- trait predictive power of the GPRS: EA-GPRS did 
not predict MDD, and MDD-GPRS did not predict EA. In the second test for genetic 
correlation, GREML analyses did not show consistent evidence for genetic correlation. The 
third test, SNP effect concordance analysis (SECA), also showed no evidence for 
concordance of EA and MDD SNP effects with respect to their significance or direction.
The GPRS in our study had within-trait predictive power in line with previous findings,7,13 
and were based on an independent EA discovery sample from the SSGAC7 of approximately 
120,000 subjects and independent MDD leave-one-cohort-out discovery samples of 
approximately 8,000 cases and 12,000 controls. These numbers seem adequate, but the 
discovery sets would ideally have been even larger, because most predictive power was still 
found for the GPRS including all SNPs (PT=1) indicating that true effect SNPs were 
associated in the discovery sample with p-values close to 1.28 Nevertheless, Dudbridge 
power calculations suggested that the EA-GPRS were well powered to predict MDD when 
the genetic correlation would have been around −0.2 (Supplementary Figure 3).35 Our 
GPRS results, therefore, indicate that a large genetic correlation between EA and MDD is 
unlikely, but could not exclude a small genetic correlation of around −0.1.
We performed GREML analyses to estimate the MDD SNP-h2, EA SNP-h2 and genetic 
correlation. The MDD SNP-h2 found (0.17) was considerably smaller than the one 
previously found by Lubke et al (0.32),10 which could well be due to the actual differences 
in SNP-h2 across cohorts; the sample of Lubke was included in the current study as 
NESDA/NTR-1 and indeed had the largest contribution to the overall SNP-h2 of all cohorts 
(Table 3). The EA SNP-h2 (0.14 in controls only) was of the same magnitude (less than 2 
SE difference) as the SNP-h2 found by Rietveld et al (0.2).7 The GREML estimate of the 
genetic correlation was somewhat complicated to interpret. A significant negative genetic 
correlation was found (−0.25, p=0.004) when EA information of both cases and controls was 
taken into account, but we fear this finding could be biased particularly in the context of 
genotype and environment correlation. In fact, when taking EA information of only controls 
into account, the estimate of genetic correlation dropped considerably and was no longer 
significant (−0.11, p=0.30). However, we note that this estimate was conservative as it 
reduced variation in EA, and we note the negative point estimate and high standard error 
showing that this analyses was underpowered to draw definitive inference. Taken all 
together, the GREML analyses could be in line with a small genetic correlation of around 
−0.1. In addition to the two methods based on individual level genotype data, we also 
performed analyses on GWAS summary statistics with the recently published SECA 
method34 and found no evidence for genetic correlation.
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To the best of our knowledge only three previous studies tested for a genetic correlation 
between MDD and EA. López-León et al used a family based approach in 2,383 subjects to 
find a negative genetic correlation of −0.65 and −0.50 between EA and self-reports of 
depressive symptoms based on respectively the Center for Epidemiologic Studies 
Depression Scale (CES-D) and the Hospital Anxiety and Depression Scale (HADS-D).11 
Boardman et al also used cross-sectional CES-D assessments and found a genetic correlation 
of −0.7 with GREML-analyses.12 Mezuk et al used a twin design with depression assessed 
with the DSM-IV based Structured Clinical Interview for Diagnostic and Statistical Manual 
of Mental Disorders (SCID-I), and their study generally supported social causation as cause 
for the link between lower EA and increased MDD risk, and found only a small genetic 
correlation of −0.22.5 The studies of López-León et al and Boardman et al contrast our 
finding of no, or at most a small, genetic correlation, but this could be because they tested 
symptom reports of depressive state at a specific point in time, whereas our study tested the 
presence of a more clinical construct: DSM-IV or ICD-10 based lifetime diagnosis of MDD. 
Indeed, our results appear in line with the findings from Mezuk et al who also used DSM-IV 
based diagnoses of MDD. Furthermore, we found that the association between lower EA and 
MDD remained when cases with an age of first MDD onset > 30 were taken into account 
exclusively. This indicates it is unlikely that MDD directly causes a lowering of EA, as it 
can be assumed that one reaches his or her education potential before the age of 30, which is 
in line with the suggested social causation by Mezuk et al.5
The finding that there is no, or at most a small, genetic correlation between lower EA and 
MDD is relevant, because this implies that non-genetic factors play an important role, and 
that underlying mechanisms may possibly be accessible to interventions. For example, when 
the social causation model would be studied in more detail, this could potentially lead to 
underlying clues on how lower socioeconomic status could contribute to vulnerability for 
MDD, or alternatively how higher socioeconomic status may buffer against vulnerability for 
MDD. For instance, lower socioeconomic status has shown to be associated to less healthy 
life styles (less physical exercise, more smoking, higher BMI, and more use of alcohol),36,37 
less adequate medical treatment seeking behavior,38 less knowledge about MDD,39 and 
higher vulnerability to experience stressful life events.40 These factors could all contribute 
to increased MDD risk. However, future research should be conducted to elucidate the most 
important underlying mechanism as these may hint to either public or personal actions to 
best prevent MDD amongst individuals with lower EA. Yet another mechanism underlying 
the link between lower EA and MDD could possibly be found in a third factor other than 
genetic effects, such as a certain personality characteristic or less developed cognitive 
abilities, that causes both lower EA and increased MDD risk.
Our study has several strengths, but also some limitations. First, our study is one of the first 
and largest studies to test for pleiotropy between lower EA and MDD, and we used 
individual level genotype data. In addition, we used clinically relevant DSM-IV and ICD-10 
based diagnoses of MDD. Furthermore, we applied three distinct methods that essentially 
lead to the same conclusion. A limitation of our study is that the discovery samples of the 
polygenic risk score analyses were not optimally sized with maximum predictive power of 
the GPRS including all SNPs (PT=1). However, this is a limitation of most current genetic 
studies, and we feel our discovery samples were adequately powered given the availability 
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of relevant genetic cohorts up to date. Furthermore, the genetic basis of MDD is strong 
enough to study pleiotropy, as has been indicated in previous work from the Psychiatric 
Genomics Consortium that indicate a genetic correlation between MDD-schizophrenia 
(0.43±0.06), and MDD-bipolar disorder (0.47±0.06) with both GREML-41 and GPRS-
analyses.42 Another limitation is that we could have missed pleiotropic effects amongst rare 
SNPs with a MAF < 0.01. This limitation could be addressed with a family or twin study, 
but it would be surprising when SNPs with MAF < 0.01 would have large pleiotropic effects 
while SNPs with MAF > 0.01 show no such evidence.
To conclude, we did confirm a negative phenotypic association between MDD and EA, but 
found no evidence that this association is due to genetic factors, which indicates that a large 
genetic correlation between lower EA and MDD is unlikely, but does not exclude a small 
genetic correlation of around −0.1. Understanding of the possible pathways between lower 
EA and MDD risk requires further research including twin analyses for an additional 
estimate of the upper bound of the genetic correlation. Nevertheless, we believe that the 
finding of the absence of large pleiotropic genetic effects underlying the established 
correlation of lower EA with increased MDD risk may be relevant, as it points to non-
genetic mechanisms that may be accessible to interventions aimed at breaking this 
deleterious link.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Forest plot of the phenotypic association between EA and MDD
The OR for MDD per SD increase in EA is displayed for the individual cohorts, as well as 
for the overall sample. The ORs were estimated with logistic regression of MDD on the 
corrected EA z-scores, which were defined as the standardized residuals of the regression of 
EA on sex, year of birth (YOB), YOB2, YOB3, and the interaction of sex with YOB, YOB2, 
and YOB3.
Peyrot et al. Page 16
Mol Psychiatry. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Peyrot et al. Page 17
Ta
bl
e 
1
Sa
m
pl
e 
ch
ar
ac
te
ris
tic
s N
 w
ith
 M
D
D
A
ge
N
 w
ith
 E
A
M
ea
n 
EA
 z
-s
co
re
St
ud
y 
(A
bb
re
via
tio
n)
C
as
e
C
on
tr
ol
M
ea
n
SD
%
 fe
m
al
e
C
as
e
C
on
tr
ol
C
as
e
C
on
tr
ol
B
on
n/
M
an
nh
ei
m
 (B
)
92
5
12
82
46
.9
13
.3
55
.7
0
0
-
-
EG
CU
T 
(E
)
50
8
53
45
48
.8
20
.1
53
.2
44
6
45
69
−
0.
06
0.
01
G
en
RE
D
 (G
E)
97
6
12
15
47
.0
16
.2
56
.1
0
11
70
-
0.
00
G
SK
 (G
S)
86
6
86
3
51
.9
13
.5
66
.9
86
6
86
2
−
0.
36
0.
36
M
PI
P 
(M
)
33
7
53
3
48
.1
13
.9
54
.5
0
0
-
-
N
ES
D
A
/N
TR
-1
 (N
1)
15
60
11
23
44
.5
13
.2
64
.3
13
82
87
5
−
0.
08
0.
12
N
ES
D
A
/N
TR
-2
 (N
2)
23
6
12
01
40
.5
14
.7
62
.4
21
1
75
9
−
0.
28
0.
09
QI
M
R 
(Q
)
14
32
16
86
43
.4
10
.9
61
.0
12
58
14
02
−
0.
02
0.
01
R
A
D
IA
N
T 
(R
)
16
05
15
73
44
.3
12
.5
66
.6
0
0
-
-
ST
A
R*
D
 (S
)
12
17
12
8
43
.5
14
.0
56
.9
12
10
12
8
−
0.
03
0.
30
O
ve
ra
ll
96
62
14
94
9
46
.2
15
.6
59
.4
53
73
97
65
−
0.
10
0.
06
Th
e 
nu
m
be
r o
f c
as
es
 w
ith
 a
 d
ia
gn
os
is 
of
 M
D
D
 in
 li
fe
tim
e,
 c
on
tro
ls 
w
ith
ou
t M
D
D
, m
ea
n 
ag
e 
an
d 
its
 st
an
da
rd
 d
ev
ia
tio
n,
 a
nd
 th
e 
pe
rc
en
ta
ge
 o
f f
em
al
e 
is 
di
sp
la
ye
d 
fo
r t
he
 te
n 
co
ho
rts
 se
pa
ra
te
ly
 a
nd
 fo
r t
he
 
o
v
er
al
l s
am
pl
e.
 In
 a
dd
iti
on
, t
he
 n
um
be
r o
f c
as
es
 a
nd
 c
on
tro
ls 
w
ith
 in
fo
rm
at
io
n 
on
 E
A
 a
va
ila
bl
e 
an
d 
th
ei
r m
ea
n 
EA
 z
-s
co
re
 a
re
 d
isp
la
ye
d.
 T
he
 E
A
 z
-s
co
re
s w
er
e 
de
fin
ed
 a
s t
he
 st
an
da
rd
iz
ed
 re
sid
ua
ls 
of
 th
e 
re
gr
es
sio
n 
of
 E
A
 o
n 
se
x,
 y
ea
r o
f b
irt
h 
(Y
OB
), Y
OB
2 ,
 
Y
O
B3
,
 
an
d 
th
e 
in
te
ra
ct
io
n 
of
 se
x 
w
ith
 Y
O
B,
 Y
O
B2
,
 
an
d 
Y
O
B3
.
Mol Psychiatry. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Peyrot et al. Page 18
Ta
bl
e 
2
Th
e 
ef
fe
ct
 o
f g
en
om
ic
 ri
sk
 p
ro
fil
e 
sc
or
es
 (G
RP
S)
, b
ase
d o
n d
ep
res
sio
n (
M
DD
-G
RP
S)
 an
d e
du
ca
tio
na
l a
tta
inm
en
t (
EA
-G
RP
S)
 di
sco
ve
ry 
res
ult
s, 
on
 M
DD
 
an
d 
EA
 in
 th
e 
ov
er
al
l s
am
pl
e 
(up
pe
r r
ow
s) 
an
d t
he
 se
pa
rat
e s
tud
ies
 (l
ow
er 
row
s).
Ef
fe
ct
 o
n 
M
D
D
N
Ef
fe
ct
R
-s
qu
ar
ed
 (%
)
Ef
fe
ct
 o
n 
EA
C
as
e
C
on
tr
ol
O
R
P-
va
lu
e
N
K
Li
ab
ili
ty
N
Be
ta
P-
va
lu
e
R
2(%
)
A
. R
es
ul
ts
 in
 o
ve
ra
ll 
sa
m
pl
e
Ef
fe
ct
 o
f M
D
D
-G
RP
S
p 
< 
0.
00
1
96
62
14
94
9
1.
03
0.
02
1
0.
03
0.
03
15
98
5
−
0.
01
0.
18
8
0.
01
p 
< 
0.
01
96
62
14
94
9
1.
04
0.
01
0
0.
04
0.
04
15
98
5
−
0.
02
0.
03
4
0.
03
p 
< 
0.
1
96
62
14
94
9
1.
11
1.
0e
-1
1
0.
28
0.
29
15
98
5
−
0.
02
0.
04
6
0.
02
p 
< 
1
96
62
14
94
9
1.
13
1.
7e
-1
6
0.
41
0.
42
15
98
5
−
0.
01
0.
06
7
0.
02
Ef
fe
ct
 o
f E
A
-G
RP
S
p 
< 
0.
00
1
65
44
12
32
4
1.
02
0.
16
7
0.
02
0.
02
13
47
7
0.
05
1.
2e
-0
9
0.
27
p 
< 
0.
01
65
44
12
32
4
1.
00
0.
84
2
0.
00
0.
00
13
47
7
0.
09
2.
4e
-2
3
0.
73
p 
< 
0.
1
65
44
12
32
4
0.
98
0.
24
5
0.
01
0.
01
13
47
7
0.
10
2.
1e
-3
1
1.
00
p 
< 
1
65
44
12
32
4
0.
99
0.
59
4
0.
00
0.
00
13
47
7
0.
11
2.
7e
-3
7
1.
20
B.
 R
es
ul
ts
 in
 se
pa
ra
te
 st
ud
ie
s
Ef
fe
ct
 o
f M
D
D
-G
RP
S 
(al
l th
res
ho
ld 
p<
1; 
let
ter
s r
ep
res
en
t s
ep
ara
te 
stu
die
s)
B
92
5
12
82
1.
14
0.
00
3
0.
54
0.
54
-
-
-
-
E
50
8
53
45
1.
10
0.
04
0
0.
16
0.
30
50
15
−
0.
01
0.
40
2
0.
01
G
E
97
6
12
15
1.
07
0.
11
1
0.
16
0.
16
11
70
−
0.
01
0.
64
7
0.
02
G
S
86
6
86
3
1.
09
0.
09
7
0.
22
0.
21
17
28
−
0.
04
0.
11
1
0.
14
M
33
7
53
3
1.
05
0.
46
1
0.
08
0.
09
-
-
-
-
N
1
15
60
11
23
1.
24
6.
1e
-0
8
1.
50
1.
50
22
57
−
0.
02
0.
37
3
0.
04
N
2
23
6
12
01
1.
19
0.
01
9
0.
70
0.
98
18
17
−
0.
02
0.
33
0
0.
05
Q
14
32
16
86
1.
09
0.
01
7
0.
25
0.
24
26
60
−
0.
01
0.
77
6
0.
00
Mol Psychiatry. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Peyrot et al. Page 19
Ef
fe
ct
 o
n 
M
D
D
N
Ef
fe
ct
R
-s
qu
ar
ed
 (%
)
Ef
fe
ct
 o
n 
EA
C
as
e
C
on
tr
ol
O
R
P-
va
lu
e
N
K
Li
ab
ili
ty
N
Be
ta
P-
va
lu
e
R
2(%
)
R
16
05
15
73
1.
15
9.
7e
-0
5
0.
65
0.
63
-
-
-
-
S
12
17
12
8
1.
17
0.
09
8
0.
45
0.
79
13
38
0.
03
0.
34
5
0.
07
Ef
fe
ct
 o
f E
A
-G
RP
S 
(al
l th
res
ho
ld 
p<
1; 
let
ter
s r
ep
res
en
t s
ep
ara
te 
stu
die
s)
E
50
8
53
45
0.
95
0.
25
7
0.
05
0.
09
50
15
0.
08
1.
2e
-0
8
0.
64
G
S
86
6
86
3
0.
96
0.
35
8
0.
07
0.
06
17
28
0.
07
0.
00
4
0.
48
M
33
7
53
3
0.
96
0.
52
4
0.
06
0.
06
-
-
-
-
N
1
15
60
11
23
0.
94
0.
15
1
0.
10
0.
10
22
57
0.
17
1.
1e
-1
5
2.
79
N
2
23
6
12
01
0.
95
0.
51
2
0.
05
0.
08
18
17
0.
16
1.
0e
-1
1
2.
52
Q
14
32
16
86
1.
00
0.
99
4
0.
00
0.
00
26
60
0.
12
1.
7e
-0
9
1.
36
R
16
05
15
73
1.
04
0.
24
1
0.
06
0.
06
-
-
-
-
Th
e 
im
pa
ct
 o
f t
he
 g
en
et
ic
 p
ro
fil
e 
ris
k 
sc
or
es
 (G
PR
S)
, b
ase
d o
n E
A 
dis
co
ve
ry 
res
ult
s (
EA
-G
PR
S)
 an
d M
DD
 di
sco
ve
ry 
res
ult
s (
M
DD
-G
PR
S)
, o
n t
arg
et 
M
DD
 an
d o
n t
arg
et 
EA
 w
ere
 es
tim
ate
d w
ith
 
re
sp
ec
tiv
el
y 
lo
gi
sti
c 
an
d 
lin
ea
r r
eg
re
ss
io
n,
 w
hi
le
 in
cl
ud
in
g 
se
x,
 th
e 
fir
st 
10
 p
rin
ci
pa
l c
om
po
ne
nt
s a
nd
 c
ov
ar
ia
te
s l
ab
el
in
g 
th
e 
co
ho
rts
 a
nd
 g
en
ot
yp
e 
ba
tc
he
s. 
Th
e 
im
pa
ct
 o
n 
M
D
D
 w
as
, i
n 
ad
di
tio
n,
 e
sti
m
at
ed
 
as
 N
ag
el
ke
rk
e’
s R
2  
an
d 
th
e 
R2
 
o
n
 th
e 
lia
bi
lit
y 
sc
al
e;
30
 
th
e 
im
pa
ct
 o
n 
EA
 a
s t
he
 st
an
da
rd
 R
2  
o
f l
in
ea
r r
eg
re
ss
io
n.
 O
n 
th
e 
ov
er
al
l s
am
pl
e,
 th
e 
ef
fe
ct
s w
er
e 
es
tim
at
ed
 fo
r G
PR
S 
on
 d
iff
er
en
t s
et
s o
f S
N
Ps
 w
ith
 
di
ffe
re
nt
 th
re
sh
ol
ds
 o
f s
ig
ni
fic
an
ce
 in
 th
e 
di
sc
ov
er
y 
se
t (
p<
0.0
01
; p
<0
.01
; p
<0
.1;
 p<
1) 
(P
an
el 
A)
. T
he
 im
pa
ct 
on
 M
DD
 an
d E
A 
in 
the
 se
pa
rat
e c
oh
ort
s w
as,
 su
bs
eq
ue
ntl
y, 
est
im
ate
d f
or 
the
 po
lyg
en
ic 
ris
k 
sc
o
re
s 
ba
se
d 
on
 a
ll 
SN
Ps
 (t
hre
sh
old
 p<
1) 
(P
an
el 
B)
. T
he
 nu
mb
er 
of 
ind
ivi
du
als
 in
clu
de
d i
n t
he
 an
aly
ses
 is
 di
sp
lay
ed
: n
ote
 th
at 
ind
ivi
du
als
 fr
om
 B
, G
E,
 an
d S
 ar
e e
xc
lud
ed
 fr
om
 th
e a
na
lys
es 
wi
th 
po
lyg
en
ic 
ris
k 
sc
or
es
 b
as
ed
 o
n 
EA
 d
isc
ov
er
y 
re
su
lts
, b
ec
au
se
 th
es
e 
co
ho
rts
 w
er
e 
(pa
rtl
y) 
inc
lud
ed
 in
 th
e d
isc
ov
ery
 ph
ase
. B
=B
on
n/M
an
nh
eim
; E
=E
GC
UT
; G
E=
Ge
nR
ED
; G
S=
GS
K;
 M
=M
PI
P; 
N1
=N
ES
DA
/N
TR
-1;
 
N
2=
N
ES
D
A
/N
TR
-2
; Q
=Q
IM
R;
 R
=R
AD
IA
NT
; S
=S
TA
R*
D
Mol Psychiatry. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Peyrot et al. Page 20
Ta
bl
e 
3
G
RE
M
L 
es
tim
at
es
 o
f t
he
 p
ro
po
rti
on
 o
f v
ar
ia
tio
n 
ex
pl
ai
ne
d 
by
 c
om
m
on
 S
N
Ps
 in
 m
ajo
r d
ep
res
siv
e d
iso
rde
r (
MD
D 
SN
P-h
2 ) 
an
d e
du
ca
tio
na
l a
tta
inm
en
t 
(E
A 
SN
P-
h2
), a
nd
 th
e g
en
eti
c c
orr
ela
tio
n b
etw
ee
n M
DD
 an
d E
A;
 es
tim
ate
d w
ith
 E
A 
inf
orm
ati
on
 fr
om
 bo
th 
ca
ses
 an
d c
on
tro
ls 
(up
pe
r r
ow
s) 
an
d f
rom
 
co
n
tr
ol
s o
nl
y 
(lo
we
r r
ow
s).
M
D
D
 S
N
P-
h2
EA
 S
N
P-
h2
G
en
et
ic
 co
rr
el
at
io
n
C
oh
or
ts
 in
cl
ud
ed
C
as
e
C
on
tr
ol
Es
t
se
p-
va
lu
e
N
Es
t
se
p-
va
lu
e
Es
t
se
p-
va
lu
e
A
. E
A
 in
 b
ot
h 
ca
se
s a
nd
 c
on
tr
ol
s
A
ll
96
62
14
94
9
0.
17
3
0.
01
7
<
1e
-1
6
15
98
5
0.
12
4
0.
01
9
2.
8e
-1
1
−
0.
25
3
0.
08
7
0.
00
4
A
ll 
ex
cl
ud
in
g 
B
87
37
13
66
7
0.
15
5
0.
01
9
1.
1e
-1
6
15
98
5
0.
12
4
0.
01
9
3.
1e
-1
1
−
0.
24
9
0.
09
6
0.
00
9
A
ll 
ex
cl
ud
in
g 
E
91
54
96
04
0.
20
7
0.
02
2
<
1e
-1
6
10
97
0
0.
13
3
0.
02
6
4.
5e
-0
7
−
0.
26
5
0.
10
2
0.
00
9
A
ll 
ex
cl
ud
in
g 
G
E
86
86
13
73
4
0.
18
3
0.
01
9
<
1e
-1
6
14
81
5
0.
13
0
0.
02
0
9.
0e
-1
1
−
0.
34
5
0.
09
1
1.
4e
-0
4
A
ll 
ex
cl
ud
in
g 
G
S
87
96
14
08
6
0.
17
2
0.
01
9
<
1e
-1
6
14
25
7
0.
12
0
0.
02
1
7.
6e
-0
9
−
0.
23
1
0.
09
9
0.
02
0
A
ll 
ex
cl
ud
in
g 
M
93
25
14
41
6
0.
17
7
0.
01
8
<
1e
-1
6
15
98
5
0.
12
4
0.
01
9
3.
9e
-1
1
−
0.
20
8
0.
08
8
0.
01
8
A
ll 
ex
cl
ud
in
g 
N
1
81
02
13
82
6
0.
15
0
0.
02
0
2.
1e
-1
4
13
72
8
0.
12
0
0.
02
2
3.
0e
-0
8
−
0.
23
9
0.
10
9
0.
02
8
A
ll 
ex
cl
ud
in
g 
N
2
94
26
13
74
8
0.
17
4
0.
01
8
<
1e
-1
6
14
16
8
0.
11
8
0.
02
1
1.
4e
-0
8
−
0.
29
4
0.
09
7
0.
00
2
A
ll 
ex
cl
ud
in
g 
Q
82
30
13
26
3
0.
19
9
0.
02
0
<
1e
-1
6
13
32
5
0.
13
3
0.
02
2
1.
6e
-0
9
−
0.
23
7
0.
09
1
0.
00
9
A
ll 
ex
cl
ud
in
g 
R
80
57
13
37
6
0.
16
1
0.
02
0
1.
0e
-1
5
15
98
5
0.
12
4
0.
01
9
3.
6e
-1
1
−
0.
20
6
0.
09
7
0.
03
3
A
ll 
ex
cl
ud
in
g 
S
84
45
14
82
1
0.
18
7
0.
01
9
<
1e
-1
6
14
64
7
0.
12
6
0.
02
0
6.
3e
-1
0
−
0.
29
4
0.
09
2
0.
00
1
B.
 E
A
 in
 c
on
tr
ol
s o
nl
y
A
ll
96
62
14
94
9
0.
17
3
0.
01
7
<
1e
-1
6
97
65
0.
14
4
0.
03
0
1.
5e
-0
6
−
0.
11
0
0.
10
5
0.
29
8
A
ll 
ex
cl
ud
in
g 
B
87
37
13
66
7
0.
15
6
0.
01
9
1.
1e
-1
6
97
65
0.
14
4
0.
03
0
1.
6e
-0
6
−
0.
11
3
0.
11
5
0.
32
7
A
ll 
ex
cl
ud
in
g 
E
91
54
96
04
0.
20
8
0.
02
2
<
1e
-1
6
51
96
0.
17
7
0.
05
4
0.
00
1
0.
00
4
0.
13
0
0.
97
2
A
ll 
ex
cl
ud
in
g 
G
E
86
86
13
73
4
0.
18
3
0.
01
9
<
1e
-1
6
85
95
0.
15
9
0.
03
4
2.
6e
-0
6
−
0.
18
7
0.
11
0
0.
08
7
A
ll 
ex
cl
ud
in
g 
G
S
87
96
14
08
6
0.
17
2
0.
01
9
<
1e
-1
6
89
03
0.
13
3
0.
03
3
4.
4e
-0
5
−
0.
12
0
0.
11
9
0.
31
0
A
ll 
ex
cl
ud
in
g 
M
93
25
14
41
6
0.
17
8
0.
01
8
<
1e
-1
6
97
65
0.
14
4
0.
03
0
1.
4e
-0
6
−
0.
06
5
0.
10
5
0.
53
7
A
ll 
ex
cl
ud
in
g 
N
1
81
02
13
82
6
0.
15
1
0.
02
0
1.
7e
-1
4
88
90
0.
14
4
0.
03
3
9.
4e
-0
6
−
0.
11
2
0.
12
4
0.
36
9
A
ll 
ex
cl
ud
in
g 
N
2
94
26
13
74
8
0.
17
4
0.
01
8
<
1e
-1
6
90
06
0.
13
2
0.
03
2
4.
0e
-0
5
−
0.
17
6
0.
11
7
0.
13
3
A
ll 
ex
cl
ud
in
g 
Q
82
30
13
26
3
0.
20
0
0.
02
0
<
1e
-1
6
83
63
0.
14
3
0.
03
5
3.
6e
-0
5
−
0.
14
8
0.
11
4
0.
19
6
A
ll 
ex
cl
ud
in
g 
R
80
57
13
37
6
0.
16
1
0.
02
0
1.
0e
-1
5
97
65
0.
14
4
0.
03
0
1.
4e
-0
6
−
0.
05
9
0.
11
6
0.
61
0
Mol Psychiatry. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Peyrot et al. Page 21
M
D
D
 S
N
P-
h2
EA
 S
N
P-
h2
G
en
et
ic
 co
rr
el
at
io
n
C
oh
or
ts
 in
cl
ud
ed
C
as
e
C
on
tr
ol
Es
t
se
p-
va
lu
e
N
Es
t
se
p-
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B
iv
ar
ia
te
- G
RE
M
L 
w
as
 p
er
fo
rm
ed
 to
 e
sti
m
at
e 
th
e 
pr
op
or
tio
n 
of
 v
ar
ia
tio
n 
ex
pl
ai
ne
d 
in
 M
D
D
 (M
DD
 SN
P-
h2
) a
nd
 E
A 
(E
A 
SN
P-
h2
) b
y g
en
om
e-w
ide
 co
mm
on
 SN
Ps
, a
s w
ell
 as
 th
e g
en
eti
c c
orr
ela
tio
n 
be
tw
ee
n 
M
D
D
 a
nd
 E
A
. F
irs
t, 
EA
 in
fo
rm
at
io
n 
of
 b
ot
h 
ca
se
s a
nd
 c
on
tro
ls 
w
as
 a
na
ly
se
d 
(fi
rst
 lin
e u
pp
er 
Pa
ne
l),
 bu
t th
e c
orr
ela
tio
n t
hu
s f
ou
nd
 sh
ou
ld 
be
 in
ter
pre
ted
 w
ith
 ca
uti
on
, b
ec
au
se 
it c
ou
ld 
be
 bi
ase
d 
(se
e M
eth
od
s).
 T
he
ref
ore
, a
na
lys
es 
we
re 
rep
ea
ted
 ta
kin
g E
A 
inf
orm
ati
on
 of
 co
ntr
ols
 on
ly 
int
o a
cc
ou
nt 
(fi
rst
 lin
e l
ow
er 
Pa
ne
l).
 In
 or
de
r t
o e
sti
ma
te 
the
 ro
bu
stn
ess
 of
 th
ese
 fi
nd
ing
s, 
the
 an
aly
ses
 w
ere
 
re
pe
at
ed
 le
av
in
g 
on
e 
co
ho
rt 
at
 th
e 
tim
e 
(ad
dit
ion
al 
lin
es 
in 
up
pe
r a
nd
 lo
we
r P
an
el)
. T
he
 M
DD
 SN
P-
h2
 
w
as
 e
x
pr
es
se
d 
on
 th
e 
lia
bi
lit
y 
sc
al
e 
as
su
m
in
g 
a 
po
pu
la
tio
n 
pr
ev
al
en
ce
 K
 o
f 2
0%
 (s
ee
 Su
pp
lem
en
tar
y 
Ta
bl
e 
5 
fo
r c
om
pa
ris
on
 o
f t
he
 M
D
D
 S
N
P-
h2
 fo
r d
iff
er
en
t v
al
ue
s o
f K
 w
ith
 th
e S
N
P-
h2
 
o
n
 th
e 
ob
se
rv
ed
 sc
al
e).
 M
DD
 w
as 
av
ail
ab
le 
for
 al
l te
n c
oh
ort
s; 
EA
 w
as 
on
ly 
av
ail
ab
le 
for
 co
ho
rts
 E
, G
E,
 G
S, 
N1
, N
2, 
Q,
 an
d S
. T
he
 an
aly
ses
 w
ere
 co
rre
cte
d f
or 
sex
, th
e f
irs
t 2
0 p
rin
cip
al 
co
mp
on
en
ts 
an
d a
 ca
teg
ori
ca
l c
ov
ari
ate
 la
be
llin
g t
he
 co
ho
rts
 an
d g
en
oty
pe
 ba
tch
es.
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eim
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=E
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; G
E=
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; 
G
S=
G
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; M
=M
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P;
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1=
N
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D
A
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; N
2=
N
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D
A
/N
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-2
; Q
=Q
IM
R;
 R
=R
AD
IA
NT
; S
=S
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R*
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